Pharmaceutical giant, Bayer, has published encouraging results from the Phase III clinical trial (OCEANIC-STROKE) of asundexian, a once-daily oral drug aimed at preventing recurrent stroke.
Asundexian represents a new class of medications known as Factor XIa (FXIa) inhibitors. FXIa is a protein involved in the blood clotting process and is crucial for the development of thrombosis (the cause of ischemic stroke). However, FXIa is relatively less involved in hemostasis—the body’s natural mechanism for stopping bleeding.
Unlike traditional anticoagulants, such as warfarin, which act on a broader part of the clotting cascade and therefore increase the risk of serious bleeding, asundexian selectively inhibits the coagulation factor FXIa (Factor XI activated).
This targeted approach to anticoagulation therapy is not new. Over the past decade, a new generation of oral anticoagulants (NOACs/DOACs) was developed, which target Factor Xa (Factor X-activated). Clear examples of these medications include rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Lixiana). These drugs were also developed at the time as a more selective therapy compared to warfarin, with a lower risk of bleeding.
Asundexian goes even further in this selectivity, as it specifically inhibits FXIa, thereby preventing the formation of thrombosis but largely preserving the clotting mechanism required for normal hemostasis. By targeting this specific protein, it may be possible to significantly reduce the incidence of thrombosis without increasing the risk of clinically significant bleeding.
The Phase III trial, OCEANIC-STROKE, was a double-blind, randomized global test involving over 12,300 participants. It investigated the efficacy of asundexian (50 mg) in combination with antiplatelet therapy.
The study met both its primary safety and efficacy endpoints in patients who had suffered an ischemic stroke or a high-risk transient ischemic attack (TIA).
-
Efficacy: The combination of asundexian significantly reduced the risk of recurrent ischemic stroke compared to placebo.
-
Safety: Crucially, there was no increase in major bleeding (as per the criteria of the International Society on Thrombosis and Haemostasis, ISTH) in the asundexian group. The study confirms that the new drug potentially provides safety, which is critically important for stroke survivors.
Christian Rommel, Head of Research and Development at Bayer Pharmaceuticals, stated: “We are excited by these positive results, which highlight the potential of Factor XIa inhibition as a new way to help protect patients from a recurrent stroke.”
In recognition of the drug’s potential, the U.S. FDA has granted asundexian Fast Track designation, which will accelerate its approval process.
